Insider Trading activities of Allos Therapeutics Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Allos Therapeutics Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Allos Therapeutics Inc since year 2005. Table 2 shows the detailed insider transactions of Allos Therapeutics Inc since 2005. The reporting company's ticker symbol is ALTH. The reporting company's CIK number is 1097264.
The total value of stock buying since 2005 is $361,891,553.
The total value of stock sales since 2005 is $73,612,871.
The total value of stock option exercises since 2005 is $3,692,124.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Allos Therapeutics Inc (ALTH).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2012-09 130,854,840 $238,155,808 0 $0 0 $0
2012-07 0 $0 697 $1,241 0 $0
2012-04 1,104 $1,342 7,970 $14,425 0 $0
2012-03 0 $0 46,010 $68,234 0 $0
2012-02 0 $0 87,069 $133,990 0 $0
2011-12 1,173 $1,415 0 $0 0 $0
2011-11 0 $0 117,191 $169,756 0 $0
2011-07 0 $0 730 $1,505 0 $0
2011-06 772 $1,404 0 $0 0 $0
2011-04 0 $0 9,800 $27,822 0 $0
2011-03 0 $0 0 $0 2,500 $7,850
2011-02 0 $0 28,103 $90,359 0 $0
2010-12 333 $1,304 0 $0 0 $0
2010-06 1,146 $5,969 0 $0 0 $0
2010-05 0 $0 3,085 $21,684 3,085 $8,684
2010-04 0 $0 75,000 $643,500 75,000 $202,500
2010-03 0 $0 119,140 $937,200 78,915 $275,195
2010-02 0 $0 55,447 $399,702 0 $0
2010-01 0 $0 317,731 $2,193,760 252,571 $610,966
2009-12 211 $1,180 0 $0 0 $0
2009-08 0 $0 550,000 $4,487,158 550,000 $1,687,850
2009-06 226 $1,165 27,500 $223,939 0 $0
2009-03 0 $0 251,200 $1,780,654 245,000 $646,139
2009-02 0 $0 6,269,295 $52,313,186 36,400 $88,051
2008-12 221 $1,149 0 $0 0 $0
2008-09 0 $0 50,000 $484,000 40,000 $96,760
2008-05 13,463,216 $75,932,535 0 $0 0 $0
2008-03 0 $0 40,500 $217,375 0 $0
2008-02 793,756 $4,967,138 0 $0 0 $0
2008-01 984,189 $7,080,128 3,000 $20,301 3,000 $7,260
2007-12 5,547 $21,594 1,500 $10,891 1,500 $3,630
2007-11 0 $0 3,000 $18,846 3,000 $7,260
2007-10 0 $0 3,000 $17,475 3,000 $7,260
2007-08 0 $0 1,500 $8,130 1,500 $3,630
2007-06 253 $460 1,571,984 $9,011,153 3,000 $7,260
2007-05 0 $0 1,500 $9,133 1,500 $3,630
2007-03 0 $0 23,625 $152,452 0 $0
2007-01 4,259,022 $25,554,132 0 $0 0 $0
2006-12 14,680 $32,859 0 $0 0 $0
2006-11 1,791,139 $10,107,242 0 $0 0 $0
2006-06 4,582 $8,333 0 $0 0 $0
2006-05 0 $0 50,000 $155,000 50,000 $28,199
2006-04 5,000 $14,700 0 $0 0 $0
2006-01 250 $572 0 $0 0 $0
2005-06 607 $1,124 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Allos Therapeutics Inc insiders (ALTH)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2012-09-05 Sapphire Acquisition Sub, Inc. (10% Owner) Buy 130,854,840 1.82 238,155,808
2012-07-11 Schick Michael E (VP, Sales and Marketing) Sale 697 1.78 1,241
2012-04-27 Morris Charles Q (Chief Medical Officer) Sale 7,970 1.81 14,425
2012-04-27 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 1,104 1.22 1,342
2012-03-01 Schick Michael E (VP, Sales and Marketing) Sale 3,960 1.48 5,864
2012-03-01 Goldsmith Bruce A (SVP, Corporate Development) Sale 4,473 1.50 6,691
2012-03-01 Graboyes Marc H (SVP, General Counsel) Sale 9,635 1.48 14,259
2012-03-01 Clark David C (VP, Finance) Sale 3,385 1.50 5,074
2012-03-01 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 3,025 1.50 4,522
2012-03-01 Berns Paul L (Chief Executive Officer) Sale 21,532 1.48 31,824
2012-02-29 Schick Michael E (VP, Sales and Marketing) Sale 3,894 1.52 5,934
2012-02-29 Goldsmith Bruce A (SVP, Corporate Development) Sale 4,505 1.52 6,870
2012-02-29 Morris Charles Q (Chief Medical Officer) Sale 10,155 1.52 15,476
2012-02-29 Graboyes Marc H (SVP, General Counsel) Sale 9,425 1.52 14,363
2012-02-29 Clark David C (VP, Finance) Sale 3,388 1.52 5,163
2012-02-29 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 3,031 1.52 4,622
2012-02-29 Berns Paul L (Chief Executive Officer) Sale 21,163 1.52 32,231
2012-02-24 Goldsmith Bruce A (SVP, Corporate Development) Sale 575 1.54 888
2012-02-24 Graboyes Marc H (SVP, General Counsel) Sale 1,380 1.54 2,125
2012-02-24 Clark David C (VP, Finance) Sale 595 1.55 922
2012-02-24 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 1,469 1.55 2,276
2012-02-24 Berns Paul L (Chief Executive Officer) Sale 4,350 1.55 6,742
2012-02-23 Schick Michael E (VP, Sales and Marketing) Sale 1,645 1.58 2,599
2012-02-23 Goldsmith Bruce A (SVP, Corporate Development) Sale 2,500 1.58 3,957
2012-02-23 Graboyes Marc H (SVP, General Counsel) Sale 3,950 1.58 6,252
2012-02-23 Clark David C (VP, Finance) Sale 1,460 1.57 2,290
2012-02-23 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 4,484 1.58 7,084
2012-02-23 Berns Paul L (Chief Executive Officer) Sale 9,100 1.56 14,196
2011-12-30 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 1,173 1.21 1,415
2011-11-16 Schick Michael E (VP, Sales and Marketing) Sale 140 1.43 200
2011-11-16 Goldsmith Bruce A (SVP, Corporate Development) Sale 300 1.43 429
2011-11-16 Clark David C (VP, Finance) Sale 125 1.43 178
2011-11-16 Berns Paul L (Chief Executive Officer) Sale 450 1.43 643
2011-11-15 Schick Michael E (VP, Sales and Marketing) Sale 8,033 1.44 11,575
2011-11-15 Goldsmith Bruce A (SVP, Corporate Development) Sale 12,465 1.44 18,011
2011-11-15 Morris Charles Q (Chief Medical Officer) Sale 17,829 1.44 25,727
2011-11-15 Graboyes Marc H (SVP, General Counsel) Sale 14,494 1.44 20,900
2011-11-15 Clark David C (VP, Finance) Sale 5,438 1.45 7,863
2011-11-15 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 26,100 1.44 37,714
2011-11-15 Berns Paul L (Chief Executive Officer) Sale 31,817 1.46 46,516
2011-07-11 Schick Michael E (VP, Sales and Marketing) Sale 730 2.06 1,505
2011-06-30 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 772 1.82 1,404
2011-04-27 Morris Charles Q (Chief Medical Officer) Sale 9,800 2.84 27,822
2011-03-17 Berns Paul L (Chief Executive Officer) Option Ex 2,500 3.14 7,850
2011-02-24 Graboyes Marc H (SVP, General Counsel) Sale 1,410 3.12 4,406
2011-02-24 Clark David C (VP, Finance) Sale 557 3.12 1,739
2011-02-24 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 1,469 3.20 4,700
2011-02-24 Berns Paul L (Chief Executive Officer) Sale 4,255 3.12 13,292
2011-02-23 Schick Michael E (VP, Sales and Marketing) Sale 1,570 3.25 5,105
2011-02-23 Graboyes Marc H (SVP, General Counsel) Sale 3,800 3.24 12,315
2011-02-23 Clark David C (VP, Finance) Sale 1,365 3.25 4,438
2011-02-23 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 4,484 3.23 14,487
2011-02-23 Berns Paul L (Chief Executive Officer) Sale 9,193 3.25 29,877
2010-12-31 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 333 3.92 1,304
2010-06-30 Graboyes Marc H (SVP, General Counsel) Buy 913 5.21 4,756
2010-06-30 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 233 5.21 1,213
2010-05-10 Clark David C (VP, Finance) Sale 3,085 7.03 21,684
2010-05-10 Clark David C (VP, Finance) Option Ex 3,085 2.82 8,684
2010-04-12 Graboyes Marc H (SVP, General Counsel) Sale 75,000 8.58 643,500
2010-04-12 Graboyes Marc H (SVP, General Counsel) Option Ex 75,000 2.70 202,500
2010-03-10 Clark David C (VP, Finance) Sale 20,000 7.78 155,620
2010-03-10 Clark David C (VP, Finance) Option Ex 20,000 4.78 95,600
2010-03-05 Clark David C (VP, Finance) Sale 10,000 7.02 70,200
2010-03-05 Clark David C (VP, Finance) Option Ex 10,000 2.93 29,300
2010-03-04 Clark David C (VP, Finance) Sale 11,640 6.98 81,305
2010-03-04 Clark David C (VP, Finance) Option Ex 8,915 2.82 25,095
2010-03-01 Caruso James V (Chief Commercial Officer) Sale 77,500 8.13 630,075
2010-03-01 Caruso James V (Chief Commercial Officer) Option Ex 40,000 3.13 125,200
2010-02-24 Graboyes Marc H (SVP, General Counsel) Sale 2,349 7.44 17,476
2010-02-24 Berns Paul L (Chief Executive Officer) Sale 7,362 7.58 55,767
2010-02-23 Graboyes Marc H (SVP, General Counsel) Sale 1,416 7.51 10,634
2010-02-23 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Sale 1,468 7.51 11,024
2010-02-23 Caruso James V (Chief Commercial Officer) Sale 5,968 7.44 44,378
2010-02-23 Berns Paul L (Chief Executive Officer) Sale 4,304 7.51 32,331
2010-02-08 Berns Paul L (Chief Executive Officer) Sale 32,580 7.00 228,092
2010-01-11 Hoffman Stephen J (Director) Sale 45,428 7.30 331,760
2010-01-11 Hoffman Stephen J (Director) Option Ex 45,428 2.42 109,890
2010-01-08 Berns Paul L (Chief Executive Officer) Sale 65,160 7.00 456,120
2010-01-08 Hoffman Stephen J (Director) Sale 45,429 7.11 322,909
2010-01-08 Hoffman Stephen J (Director) Option Ex 45,429 2.42 109,892
2010-01-07 Hoffman Stephen J (Director) Sale 45,429 6.76 307,100
2010-01-07 Hoffman Stephen J (Director) Option Ex 45,429 2.42 109,892
2010-01-06 Hoffman Stephen J (Director) Sale 45,429 6.78 308,144
2010-01-06 Hoffman Stephen J (Director) Option Ex 45,429 2.42 109,892
2010-01-05 Hoffman Stephen J (Director) Sale 45,428 6.64 301,505
2010-01-05 Hoffman Stephen J (Director) Option Ex 45,428 2.42 109,890
2010-01-04 Hoffman Stephen J (Director) Sale 25,428 6.54 166,222
2010-01-04 Hoffman Stephen J (Director) Option Ex 25,428 2.42 61,510
2009-12-31 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 211 5.59 1,180
2009-08-10 Caruso James V (Chief Commercial Officer) Sale 85,400 8.13 694,302
2009-08-10 Caruso James V (Chief Commercial Officer) Option Ex 85,400 3.13 267,302
2009-08-10 Berns Paul L (Chief Executive Officer) Sale 342,000 8.24 2,819,448
2009-08-10 Berns Paul L (Chief Executive Officer) Option Ex 342,000 3.14 1,073,880
2009-08-05 Caruso James V (Chief Commercial Officer) Sale 14,600 8.13 118,756
2009-08-05 Caruso James V (Chief Commercial Officer) Option Ex 14,600 3.13 45,698
2009-08-05 Berns Paul L (Chief Executive Officer) Sale 8,000 8.14 65,152
2009-08-05 Berns Paul L (Chief Executive Officer) Option Ex 8,000 3.14 25,120
2009-08-03 Graboyes Marc H (VP, General Counsel) Sale 50,000 8.00 400,000
2009-08-03 Graboyes Marc H (VP, General Counsel) Option Ex 50,000 2.39 119,350
2009-08-03 Caruso James V (Chief Commercial Officer) Sale 50,000 7.79 389,500
2009-08-03 Caruso James V (Chief Commercial Officer) Option Ex 50,000 3.13 156,500
2009-06-30 Bennett Bruce K Jr (VP, Pharmaceutical Operations) Buy 226 5.16 1,165
2009-06-16 Caruso James V (Chief Commercial Officer) Sale 13,500 8.16 110,119
2009-06-15 Caruso James V (Chief Commercial Officer) Sale 14,000 8.13 113,820
2009-03-26 Caruso James V (Chief Commercial Officer) Sale 39,500 7.37 291,194
2009-03-26 Caruso James V (Chief Commercial Officer) Option Ex 39,500 3.13 123,635
2009-03-25 Caruso James V (Chief Commercial Officer) Sale 6,900 7.13 49,203
2009-03-25 Caruso James V (Chief Commercial Officer) Option Ex 6,900 3.13 21,597
2009-03-20 Cagnoni Pablo J (Sr. VP, Chief Medical Officer) Sale 6,200 6.62 41,075
2009-03-16 Caruso James V (Chief Commercial Officer) Sale 3,600 7.13 25,671
2009-03-16 Caruso James V (Chief Commercial Officer) Option Ex 3,600 3.13 11,268
2009-03-13 Graboyes Marc H (VP, General Counsel) Sale 5,864 7.00 41,048
2009-03-13 Graboyes Marc H (VP, General Counsel) Option Ex 5,864 2.00 11,728
2009-03-13 Clark David C (VP, Finance) Sale 5,027 7.00 35,189
2009-03-13 Clark David C (VP, Finance) Option Ex 5,027 2.93 14,729
2009-03-12 Graboyes Marc H (VP, General Counsel) Sale 69,136 7.02 484,989
2009-03-12 Graboyes Marc H (VP, General Counsel) Option Ex 69,136 2.00 138,272
2009-03-12 Clark David C (VP, Finance) Sale 64,973 7.02 455,785
2009-03-12 Clark David C (VP, Finance) Option Ex 64,973 2.59 168,410
2009-03-12 Caruso James V (Chief Commercial Officer) Sale 50,000 7.13 356,500
2009-03-12 Caruso James V (Chief Commercial Officer) Option Ex 50,000 3.13 156,500
2009-02-06 Baker Felix (10% Owner) Sale 1,050,936 8.21 8,633,426
2009-02-05 Baker Felix (10% Owner) Sale 520,245 8.15 4,237,913
2009-02-04 Hoffman Stephen J (Director) Sale 36,400 9.03 328,692
2009-02-04 Hoffman Stephen J (Director) Option Ex 36,400 2.42 88,051
2009-02-04 Baker Felix (10% Owner) Sale 1,545,581 8.49 13,123,526
2008-12-31 Bennett Bruce K Jr (VP, Manufacturing) Buy 221 5.20 1,149
2008-09-02 Caruso James V (Chief Commercial Officer) Sale 10,000 9.68 96,800
2008-09-02 Hoffman Stephen J Sale 40,000 9.68 387,200
2008-09-02 Hoffman Stephen J Option Ex 40,000 2.42 96,760
2008-05-29 Leff Jonathan S (Director) Buy 3,500,000 5.64 19,740,000
2008-05-29 Hen Stewart (Director) Buy 3,500,000 5.64 19,740,000
2008-05-29 Warburg Pincus Private Equity Viii L P (Director) Buy 3,500,000 5.64 19,740,000
2008-05-22 Baker Felix (10% Owner) Buy 1,500,000 5.64 8,459,998
2008-03-20 Cagnoni Pablo J (Sr. VP, Chief Medical Officer) Sale 6,100 5.29 32,269
2008-03-10 Berns Paul L (Chief Executive Officer) Sale 34,400 5.38 185,106
2008-02-25 Baker Felix (10% Owner) Buy 100,000 6.00 600,000
2008-02-21 Baker Felix (10% Owner) Buy 145,000 6.05 877,247
2008-02-20 Baker Felix (10% Owner) Buy 76,380 6.50 496,391
2008-02-19 Baker Felix (10% Owner) Buy 75,713 6.75 511,288
2008-01-23 Baker Felix (10% Owner) Buy 20,677 6.95 143,724
2008-01-22 Baker Felix (10% Owner) Buy 747 6.92 5,164
2008-01-18 Baker Felix (10% Owner) Buy 12,424 7.18 89,251
2008-01-15 Baker Felix (10% Owner) Buy 26,000 7.50 194,999
2008-01-14 Baker Felix (10% Owner) Buy 130,000 7.41 963,817
2008-01-11 Baker Felix (10% Owner) Buy 55,000 7.47 411,012
2008-01-10 Baker Felix (10% Owner) Buy 115,800 7.47 864,908
2008-01-09 Baker Felix (10% Owner) Buy 62,400 6.96 434,303
2008-01-08 Baker Felix (10% Owner) Buy 200,000 7.21 1,442,198
2008-01-07 Johnson Douglas G (VP of Manufacturing) Sale 1,500 7.24 10,860
2008-01-07 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2008-01-07 Baker Felix (10% Owner) Buy 101,444 6.53 662,340
2008-01-02 Johnson Douglas G (VP of Manufacturing) Sale 1,500 6.29 9,441
2008-01-02 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-12-31 Johnson Douglas G (VP of Manufacturing) Buy 547 3.89 2,129
2007-12-31 Berns Paul L (Chief Executive Officer) Buy 5,000 3.89 19,465
2007-12-03 Johnson Douglas G (VP of Manufacturing) Sale 1,500 7.26 10,891
2007-12-03 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-11-28 Johnson Douglas G (VP of Manufacturing) Sale 1,500 6.72 10,080
2007-11-28 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-11-01 Johnson Douglas G (VP of Manufacturing) Sale 1,500 5.84 8,766
2007-11-01 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-10-15 Johnson Douglas G (VP of Manufacturing) Sale 1,500 6.23 9,345
2007-10-15 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-10-05 Johnson Douglas G (VP of Manufacturing) Sale 1,500 5.42 8,130
2007-10-05 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-08-10 Johnson Douglas G (VP of Manufacturing) Sale 1,500 5.42 8,130
2007-08-10 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-06-29 Johnson Douglas G (VP of Manufacturing) Buy 253 1.82 460
2007-06-21 Baker Felix (10% Owner) Sale 89,700 5.55 497,923
2007-06-19 Johnson Douglas G (VP of Manufacturing) Sale 1,500 6.63 9,945
2007-06-19 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-06-19 Baker Felix (10% Owner) Sale 1,098,313 5.75 6,312,001
2007-06-06 Caruso James V (Chief Commercial Officer) Sale 10,000 5.62 56,150
2007-06-01 Johnson Douglas G (VP of Manufacturing) Sale 1,500 5.77 8,658
2007-06-01 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-05-04 Johnson Douglas G (VP of Manufacturing) Sale 1,500 6.09 9,133
2007-05-04 Johnson Douglas G (VP of Manufacturing) Option Ex 1,500 2.42 3,630
2007-03-12 Berns Paul L (Chief Executive Officer) Sale 23,625 6.45 152,452
2007-01-29 Baker Felix (10% Owner) Buy 3,300,000 6.00 19,800,000
2006-12-29 Malek Eric (VP of Corporate Development) Buy 1,223 1.82 2,224
2006-12-29 Saunders Michael E (VP, Clinical Development) Buy 2,500 1.82 4,547
2006-12-29 Graboyes Marc H (VP, General Counsel) Buy 2,500 1.82 4,547
2006-12-29 Johnson Douglas G (VP of Manufacturing) Buy 2,247 1.82 4,087
2006-12-29 Herzig Markus F (VP Regulatory Affairs) Buy 1,210 1.82 2,200
2006-12-29 Caruso James V (Chief Commercial Officer) Buy 2,500 3.05 7,627
2006-12-29 Berns Paul L (Chief Executive Officer) Buy 2,500 3.05 7,627
2006-11-28 Baker Felix (10% Owner) Buy 300,000 5.50 1,649,999
2006-11-17 Baker Felix (10% Owner) Buy 115,000 5.75 660,789
2006-11-16 Baker Felix (10% Owner) Buy 155,000 5.80 899,309
2006-11-15 Baker Felix (10% Owner) Buy 460,000 5.66 2,602,219
2006-06-30 Malek Eric (VP of Corporate Development) Buy 1,209 1.82 2,199
2006-06-30 Graboyes Marc H (VP, General Counsel) Buy 1,888 1.82 3,434
2006-06-30 Johnson Douglas G (VP of Manufacturing) Buy 195 1.82 354
2006-06-30 Herzig Markus F (VP Regulatory Affairs) Buy 1,290 1.82 2,346
2006-05-26 Hart Michael E Sale 50,000 3.10 155,000
2006-05-26 Hart Michael E Option Ex 50,000 .56 28,199
2006-04-13 Berns Paul L (Chief Executive Officer) Buy 5,000 2.94 14,700
2006-01-17 Herzig Markus F (VP Regulatory Affair) Buy 250 2.29 572
2005-06-30 Clark David C (Controller) Buy 272 1.85 504
2005-06-30 Johnson Douglas G (VP of Manufacturing) Buy 335 1.85 620

Insider trading activities including stock purchases, stock sales, and option exercises of ALTH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Allos Therapeutics Inc (symbol ALTH, CIK number 1097264) see the Securities and Exchange Commission (SEC) website.